Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 05, 2019
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 18, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
Journal: Science (New York, N.Y.)
Published: November 10, 2017
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Journal: Science (New York, N.Y.)
Published: May 17, 2017
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus.
Journal: Cancer prevention research (Philadelphia, Pa.)
Published: October 07, 2014
Showing 1-5 of 5
Last Updated: 09/26/2026